FSI, an asset management company agreed to acquire a 19.59% stake in Kedrion, a developer and distributor of plasma-derived medicinal products for $150m. The closing of the transaction will be subject to the approval from the competent Antitrust Authorities. Kedrion is a player in the plasma-derivatives market in Italy. In the last decade, Kedrion has grown internationally to become the fifth player worldwide in an industry that has been characterized by a constant growth in recent years. Kedrion has its headquarters in Castelvecchio Pascoli (Italy), operates through its 4 manufacturing sites and 26 plasma collection centers, and has over 2.5k employees, of which over 1k are based in Italy.